ReviewTherapeutic advances in hematology2022

Selecting the optimal BTK inhibitor therapy in CLL: rationale and practical considerations.

Alexandra R Lovell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.